Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Employee Benefits

Biden administration identifies 27 drugs facing penalties for cost hikes

March 17, 2023 Reprints

The Biden administration announced the first set of pharmaceutical companies that will face penalties for raising prices within Medicare faster than the rate of inflation, Healthcare Dive reports. The list of 27 drugs includes AbbVie Inc.’s top-selling inflammatory disease drug Humira as well as Seagen Inc.’s bladder cancer drug Padcev and Gilead Sciences Inc.’s cancer cell therapies Yescarta and Tecartus. Five Pfizer Inc. drugs are on the list – the most of any drugmaker.

Help

Biden administration identifies 27 drugs facing penalties for cost hikes

Readers Poll

Most Read in Employee Benefits

Sign up now for free access to this article and much more.

If you are already registered with Business Insurance, click here to Login

Please tell us a bit more about yourself in order to continue

About

Advertise

Reprints and Licensing

Resources